Detecting KMT2A Partial Tandem Duplication in Blood Cancers
Author Information
Author(s): Wei Qing, Hu Shimin, Xu Jie, Loghavi Sanam, Daver Naval, Toruner Gokce A., Wang Wei, Medeiros L. Jeffrey, Tang Guilin
Primary Institution: MD Anderson Cancer Center, The University of Texas
Hypothesis
Can optical genome mapping effectively detect KMT2A partial tandem duplication in myeloid neoplasms?
Conclusion
Optical genome mapping is an effective tool for detecting KMT2A partial tandem duplication, which is associated with poor treatment responses and outcomes in myeloid neoplasms.
Supporting Evidence
- KMT2A PTD was detected in 35 patients with acute myeloid leukemia (AML), 5 with myelodysplastic syndrome (MDS), and 5 with chronic myelomonocytic leukemia (CMML).
- Patients with KMT2A PTD are generally resistant to conventional chemotherapy, except for those with de novo AML, which shows a high remission rate.
- Optical genome mapping identified KMT2A PTD as a sole abnormality in 20 patients and with additional cytogenomic abnormalities in 25 patients.
Takeaway
This study looked at a special change in a gene called KMT2A in blood cancers and found that a new method can help find it better, which is important for treating patients.
Methodology
The study used optical genome mapping to analyze cytogenomic alterations in 1277 hematolymphoid neoplasms.
Limitations
The study did not evaluate KMT2A PTD at multiple time points, making it unclear if the PTD was acquired during disease progression.
Participant Demographics
The cohort included 31 men and 14 women with a median age of 68 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website